Researcher:
Özkan, Ahu

Loading...
Profile Picture
ORCID

Job Title

Doctor

First Name

Ahu

Last Name

Özkan

Name

Name Variants

Özkan, Ahu

Email Address

Birth Date

Search Results

Now showing 1 - 1 of 1
  • Placeholder
    Publication
    Extramedullary relapsed multiple myeloma treatment with 177Lu-Labeled CXCR4 endoradiotherapy and dosimetric results
    (Lippincott Williams & Wilkins, 2021) Uçar, Burcu; Wester, Hans-Juergen; Demirkol, Mehmet Onur; Özkan, Ahu; Ferhanoğlu, Ahmet Burhan; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; 196946; N/A; 18320
    We created our first national clinical protocol of Lu-177-CXCR4 therapy for patient who have failed to respond to current therapy options. We also calculated the kidney, liver, and tumor dosimetry. The kidney's mean absorbed dose was calculated to be 0.45 Gy/GBq, the calculated radiation absorbed dose of the liver was 0.63 Gy/GBq, and the radiation absorbed doses of the tumors vary between 9.2 and 82 Gy/GBq. Lu-177-CXCR4 therapy produced a promising clinical response in our patient in acceptable radiation dose limits as a treatment option in heavily pretreated patients with advanced multiple myeloma.